Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem BioAssay

Items: 19

1.

Structure-function based design of small molecule inhibitors targeting Rho family GTPases.

Nassar N, Cancelas J, Zheng J, Williams DA, Zheng Y.

Curr Top Med Chem. 2006;6(11):1109-16. Review.

PMID:
16842149
2.

Bisphosphonates: from bench to bedside.

Russell RG.

Ann N Y Acad Sci. 2006 Apr;1068:367-401. Review.

PMID:
16831938
3.

Lonafarnib in cancer therapy.

Morgillo F, Lee HY.

Expert Opin Investig Drugs. 2006 Jun;15(6):709-19. Review.

PMID:
16732721
4.

The Ras superfamily at a glance.

Wennerberg K, Rossman KL, Der CJ.

J Cell Sci. 2005 Mar 1;118(Pt 5):843-6. Review. No abstract available.

5.

A novel RAB7 mutation associated with ulcero-mutilating neuropathy.

Houlden H, King RH, Muddle JR, Warner TT, Reilly MM, Orrell RW, Ginsberg L.

Ann Neurol. 2004 Oct;56(4):586-90.

PMID:
15455439
6.

Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.

Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y.

Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23. Epub 2004 May 5.

7.

High-throughput flow cytometry: validation in microvolume bioassays.

Ramirez S, Aiken CT, Andrzejewski B, Sklar LA, Edwards BS.

Cytometry A. 2003 May;53(1):55-65.

8.

Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy.

Verhoeven K, De Jonghe P, Coen K, Verpoorten N, Auer-Grumbach M, Kwon JM, FitzPatrick D, Schmedding E, De Vriendt E, Jacobs A, Van Gerwen V, Wagner K, Hartung HP, Timmerman V.

Am J Hum Genet. 2003 Mar;72(3):722-7. Epub 2003 Jan 21.

9.

Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome.

Bahadoran P, Busca R, Chiaverini C, Westbroek W, Lambert J, Bille K, Valony G, Fukuda M, Naeyaert JM, Ortonne JP, Ballotti R.

J Biol Chem. 2003 Mar 28;278(13):11386-92. Epub 2003 Jan 16.

10.

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.

Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB.

Circ Res. 2002 Jul 26;91(2):143-50.

11.

High throughput flow cytometry.

Kuckuck FW, Edwards BS, Sklar LA.

Cytometry. 2001 May 1;44(1):83-90.

PMID:
11309812
12.

Small GTP-binding proteins.

Takai Y, Sasaki T, Matozaki T.

Physiol Rev. 2001 Jan;81(1):153-208. Review.

13.

Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency.

Williams DA, Tao W, Yang F, Kim C, Gu Y, Mansfield P, Levine JE, Petryniak B, Derrow CW, Harris C, Jia B, Zheng Y, Ambruso DR, Lowe JB, Atkinson SJ, Dinauer MC, Boxer L.

Blood. 2000 Sep 1;96(5):1646-54.

14.

Mutant ras epitopes as targets for cancer vaccines.

Abrams SI, Hand PH, Tsang KY, Schlom J.

Semin Oncol. 1996 Feb;23(1):118-34. Review.

PMID:
8607022
15.

K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL.

Am J Pathol. 1993 Aug;143(2):545-54. Review.

16.

Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M, Wigler M.

Nature. 1982 Dec 23;300(5894):762-5.

PMID:
7177195
17.

Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations.

Sukumar S, Notario V, Martin-Zanca D, Barbacid M.

Nature. 1983 Dec 15-21;306(5944):658-61.

PMID:
6318112
18.

Role of the Ha-ras (RasH) oncogene in mediating progression of the tumor cell phenotype (review).

Boylan JF, Jackson J, Steiner MR, Shih TY, Duigou GJ, Roszman T, Fisher PB, Zimmer SG.

Anticancer Res. 1990 May-Jun;10(3):717-24. Review.

PMID:
2195986
19.

Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain.

Farnsworth CL, Marshall MS, Gibbs JB, Stacey DW, Feig LA.

Cell. 1991 Feb 8;64(3):625-33.

PMID:
1899358
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk